Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier

    FirstTest

    November 2015 - Building on the success of the program in previous years, again in 2015 the iCMLf offers seed funding to hematology institutions in emerging economic regions to build local capacity for CML testing. From the applications this year the iCMLf Directors have selected 10 projects for seed funding to build CML capacity in the emerging regions. Countries include; Bolivia, Honduras, India, Indonesia, Kenya, Macedonia, Niger and Nigeria.

    The successful centres are the following:

    1. All India Institute of Medical Sciences, New Delhi (India)
    2. National Hospital of Zinder (Niger)
    3. Instituto Oncológico del Oriente de Bolivia (Bolivia)
    4. Centro de Cáncer Emma Romero de Callejas (Honduras)
    5. Ulin General Hospital, Banjarsamin, South Kalimantan (Indonesia)
    6. University of Nairobi/Kenyatta National Hospital, Nairobi (Kenya)
    7. University Clinic for Hematology, Faculty of Medicine, Skopje (Macedonia)
    8. National Hospital Abuja, Abuja (Nigeria)
    9. Prince Aly Khan Hospital, Mumbai (India)
    10. Obafemi Awolowo University, Ile Ife (Nigeria)

    iCMLf grants are provided for projects that will increase local access to CML diagnostics, thereby building local capacity. The projects submitted in 2015 represent a broad range of different approaches to increase local capacity to conduct diagnostic testing for CML patients.

    Expected outcomes in 2015:

    Patient impact in 12 months 4,059

     

    Provide molecular monitoring 8 centres
    Enhanced laboratory capacity 8 centres
    Establish local PCR 3 centres
    Established as a referral centre 3 centres
    Physician training 2 centres
    Patient education 1 centre


    The institutions awarded grants will partner with a CML centre of excellence that will offer ongoing mentoring and support at a clinical and laboratory level. This will ensure the successful implementation of each project. 

    The phase I seeding grants comprise funding of up to $10,000. Phase II funding is for previous awardees only that have achieved outstanding results with initial funds and can be up to $20,000.